Gut microbiome as a response marker for pancreatic enzyme replacement therapy in a porcine model of exocrine pancreas insufficiency.

Sabrina RitzDaniela HahnHaleluya T WamiKarin TegelkampUlrich DobrindtJuergen Schnekenburger

Published in: Microbial cell factories (2020)

These data demonstrate that EPI-induced dysbiosis could be reverted by PERT to a nearly healthy state. Elevated α-diversity and the reduction of bacterial overgrowth after PERT promises benefits for EPI patients. Non-invasive microbiome studies may be useful for EPI therapy monitoring and as marker for response to PERT.

Keyphrases

replacement therapy
end stage renal disease
ejection fraction
newly diagnosed
smoking cessation
prognostic factors
peritoneal dialysis
high glucose
oxidative stress
endothelial cells
patient reported outcomes
machine learning
drug induced
bone marrow
patient reported